The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...

Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is ...